84,920 results match your criteria Lupus [Journal]


From A to D: A Unique Case Report of Recovery after Longitudinal Myelitis Related to Lupus.

Am J Phys Med Rehabil 2018 Dec 14. Epub 2018 Dec 14.

HealthPartners Neuroscience Center, St. Paul, MN, USA.

Longitudinal myelitis secondary to an acute flare of systemic lupus erythematosus (SLE) has been reported in the literature. There have been few published cases of complete functional recovery in patients with systemic lupus erythematosus related longitudinal myelitis (SLE-LM). Of those cases, none have described in detail the rehabilitation course of treatment. Read More

View Article
December 2018
1 Read

What's wrong with neutrophils in lupus?

Clin Exp Rheumatol 2018 Nov 19. Epub 2018 Nov 19.

Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

Polymorphonuclear neutrophils (PMNs) act by promoting phagocytosis, and are regarded as the first line of defense against pathogen invasion. However, recent investigations have revealed that they have many previously unknown functions. These functions include mitogen-induced cell-mediated cytotoxicity, production of cytokines/chemokines/growth factors, and release of neutrophil extracellular traps (NETs) and ectosomes/exosomes. Read More

View Article
November 2018

Remission of proteinuria under therapeutic intervention and the renal outcomes in Japanese patients with lupus nephritis class III and IV.

Mod Rheumatol 2018 Dec 17:1-17. Epub 2018 Dec 17.

a Division of Nephrology and Hypertension, Department of Internal Medicine , The Jikei University School of Medicine , Tokyo , Japan.

Background: Recent studies have identified the significance of proteinuria levels after initial induction therapies on the renal outcomes in patients with proliferative lupus nephritis, but the issue has not been evaluated in Japanese patients.

Methods: Based on the ISN/RPS classification, only patients diagnosed as lupus nephritis class III or IV were included. The remission of proteinuria twelve months after diagnosis, as well as the clinicopathological features at diagnosis, on renal outcomes was examined retrospectively. Read More

View Article
December 2018

Ocular Posterior Segment Involvement in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus.

Ocul Immunol Inflamm 2018 Dec 17:1-6. Epub 2018 Dec 17.

d Department of Ophthalmology , Marmara University School of Medicine , Istanbul , Turkey.

Purpose: To describe posterior segment findings of antiphospholipid syndrome (APS) and compare them with systemic lupus erythematosus (SLE).

Methods: A total of 11 patients with primary APS, 29 secondary APS patients, and 29 SLE patients without APS were included. All patients were referred from rheumatology clinic for detailed ophthalmologic examination. Read More

View Article
December 2018

Allergy inhibitory receptor-1 inhibits autoantibody production via upregulation of apoptotic debris clearance by macrophages.

Int J Rheum Dis 2018 Dec 16. Epub 2018 Dec 16.

Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Aim: Allergy inhibitory receptor-1 (Allergin-1) is a newly identified immune regulatory molecule thought to influence autoantibody production. Autoantibody production, like that observed in Allergin-1-deficient mice, is crucial in the pathogenesis of several autoimmune diseases such as systemic lupus erythematosus. The purpose of this study is to clarify the regulatory role of Allergin-1-mediated autoantibody production using a murine model of thymocytic anaphylaxis. Read More

View Article
December 2018

Lupus pernio (Besnier-Tenneson syndrome): A rare form of sarcoidosis.

Dermatol Reports 2018 Oct 1;10(2):7696. Epub 2018 Oct 1.

Hospital of Skin and Venereal Disease Hospital named after VA Rakhmanov. I.M. Sechenov First Moscow State Medical University, Moscow, Russia.

Lupus pernio (LP) is a chronic non-life threatining type of cutaneous sarcoidosis that can be related to chronic fibrotic sarcoidosis, hyperglobulinemia and hypercalcemia. The aim of this case report is to evaluate the clinical and demographic features of cutaneous sarcoidosis mainly presenting with a rare manifestation of LP. In this paper we report a case of systemic sarcoidosis presenting with LP and a review of the available literature. Read More

View Article
October 2018

Erysipelothrix rhusiopathiae septicaemia in systemic lupus erythematosus.

Infez Med 2018 Dec;26(4):356-358

Department of Infectious Diseases, Galliera Hospital, Genoa, Italy.

Erysipelothrix rhusiopathiae is a Gram-positive bacillus that is rarely reported as a causative agent of infections in humans. Human cases in most instances present as localized or generalized skin infections. Invasive infections are exceptionally described and septic forms are usually associated with endocarditis. Read More

View Article
December 2018

Tuftsin phosphorylcholine-a novel compound harnessing helminths to fight autoimmunity.

Immunol Res 2018 Dec 15. Epub 2018 Dec 15.

Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.

The distinction that in areas where helminthic infections are common, autoimmune diseases are less prevalent, led to the investigation of immune modulatory properties of helminths and their derivatives. Such are phosphorylcholine (PC) moieties which are a component of secreted products of helminths. PC has been broadly studied for its attenuating effects on the human immune system. Read More

View Article
December 2018
1 Read

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

J Rheumatol 2018 Dec 15. Epub 2018 Dec 15.

S.R. Johnson MD PhD FRCPC, Division of Rheumatology, Department of Medicine, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. D. Khanna MD MS, Division of Rheumatology, Department of Medicine, University of Michigan, USA. R. Cervera MD PhD FRCP, Hospital Clínic, Barcelona, Spain. N. Costedoat-Chalumeau MD PhD AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, Paris, France ; Université Paris Descartes-Sorbonne Paris Cité, Paris, France ; INSERM U 1153, Center for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France. D.D. Gladman MD FRCPC, Division of Rheumatology, Department of Medicine, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. B.H. Hahn MD, University of California Los Angeles, Los Angeles, USA. F. Hiepe MD, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Charitéplatz 1, 10117 Berlin, Germany. J. Sánchez-Guerrero MD MSc, Division of Rheumatology, Department of Medicine Mount Sinai Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada; and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. E. Massarotti MD, Brigham and Women's Hospital, Boston MA; Harvard Medical School, Boston, USA. D.T. Boumpas MD FACP FACR, National and Kapodestrian University of Athens, and Biomedical Research Foundation of the Athens Academy, Athens, Greece. K.H Costenbader MD MPH, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, USA. D. Daikh MD, University of California, San Francisco, USA. D. Jayne MD FRCP FRCPE FMedSci, Department of Medicine, University of Cambridge, United Kingdom. T. Dörner MD, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Charitéplatz 1, 10117 Berlin, Germany. D.L. Kamen MD MSCR, Medical University of South Carolina, Charleston, USA. M. Mosca MD PhD, University of Pisa, Italy. R. Ramsey-Goldman MD DrPH, Northwestern University Feinberg School of Medicine, Chicago, USA. J.S. Smolen MD, Medical University of Vienna, Austria. D. Wofsy MD, University of California, San Francisco, USA. M. Aringer MD, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany. Address correspondence to Sindhu Johnson MD PhD, Division of Rheumatology, Ground Floor, East Wing, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada, M5T 2S8. Phone 1-416-603-6417 Fax.1-416-603- 4348. Email:

Objective: Given the complexity and heterogeneity of systemic lupus erythematosus (SLE), high performing classification criteria are critical to advancing research and clinical care. A collaborative effort by EULAR and ACR was undertaken to generate candidate criteria, and then to reduce them to a smaller set. The objective of the current study was to select a set of criteria that maximizes the likelihood of accurate classification of SLE, particularly early disease. Read More

View Article
December 2018

Abnormal Nailfold Capillaroscopy Is Common in Patients with Connective Tissue Disease and Associated with Abnormal Pulmonary Function Tests.

J Rheumatol 2018 Dec 15. Epub 2018 Dec 15.

From the Department of Internal Medicine, Division of Vascular Medicine, and the Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. A.M. van Roon, Department of Internal Medicine, Division of Vascular Medicine, University of Groningen, University Medical Center Groningen; C.C. Huisman, Department of Internal Medicine, Division of Vascular Medicine, University of Groningen, University Medical Center Groningen; A.M. van Roon, PhD, Department of Internal Medicine, Division of Vascular Medicine, University of Groningen, University Medical Center Groningen; D. Zhang, MD, Department of Rheumatology, Medical Center Leeuwarden; A.J. Stel, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; A.J. Smit, MD, PhD, Department of Internal Medicine, Division of Vascular Medicine, University of Groningen, University Medical Center Groningen; H. Bootsma, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; D.J. Mulder, MD, PhD, Department of Internal Medicine, Division of Vascular Medicine, University of Groningen, University Medical Center Groningen. Address correspondence to A.M. van Roon, Department of Internal Medicine, Division of Vascular Medicine, University Medical Center Groningen, Huispostcode AA41, Hanzeplein 1, Postbus 30 001, Groningen, the Netherlands. E-mail: Accepted for publication September 11, 2018.

Objective: To assess the presence of a systemic sclerosis (SSc) pattern on nailfold capillary microscopy (NCM) in patients with Raynaud phenomenon (RP) and to explore its association with abnormal pulmonary function tests (PFT).

Methods: NCM patterns were assessed in 759 consecutive patients with RP. Patterns were classified as normal (n = 354), nonspecific (n = 159), or SSc pattern (n = 246). Read More

View Article
December 2018

Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision.

Life Sci 2018 Dec 12. Epub 2018 Dec 12.

Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. Electronic address:

Cyclophosphamide (CP) is an important anticancer drug which belongs to the class of alkylating agent. Cyclophosphamide is mostly used in bone marrow transplantation, rheumatoid arthritis, lupus erythematosus, multiple sclerosis, neuroblastoma and other types of cancer. Dose-related cardiotoxicity is a limiting factor for its use. Read More

View Article
December 2018
1 Read

Molecular mimicry, genetic homology, and gene sharing proteomic "molecular fingerprints" using an EBV (Epstein-Barr virus)-derived microarray as a potential diagnostic method in autoimmune disease.

Immunol Res 2018 Dec 15. Epub 2018 Dec 15.

Rheumatology, Boston University School of Medicine, Arthritis Center, 72 E. Concord Street, E-5, Boston, MA, 02118, USA.

EBV (Epstein-Barr Virus) and other human DNA viruses are associated with autoimmune syndromes in epidemiologic studies. In this work, immunoglobulin G response to EBV-encoded proteins which share regions with human immune response proteins from the human host including ZEBRA (BZLF-1 encoded protein), BALF-2 recombinase expressed primarily during the viral lytic replication cycle, and EBNA-1 (Epstein-Barr Virus Nuclear Antigen) expressed during the viral latency cycle respectively were characterized using a laser-printed micro-array ( PEPperprint.com ). Read More

View Article
December 2018
1 Read

Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study.

Ann Rheum Dis 2018 Dec 14. Epub 2018 Dec 14.

Center of Research of Immunopathology and Rare Diseases- Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

View Article
December 2018

Principal component analysis reveals disconnect between regulatory cytokines and disease activity in Systemic Lupus Erythematosus.

Cytokine 2018 Dec 11. Epub 2018 Dec 11.

Rheumatology Group, School of Medicine & Pharmacology, The University of Western Australia, Australia; Department of Rheumatology, Sir Charles Gairdner Hospital, Perth Western, Australia. Electronic address:

Objective: Cytokine dysregulation contributes to inflammation and organ damage in Systemic Lupus Erythematosus (SLE). Principle Component Analysis (PCA) can determine which groups of cytokines have the most influence across disease activity states.

Material And Method: A cross-sectional study of age- and gender-matched SLE patients (n = 100) and controls (n = 31). Read More

View Article
December 2018

[Exploring illness perceptions of lupus patients for a motivational environment in therapeutic education].

Rev Med Interne 2018 Dec 11. Epub 2018 Dec 11.

Service de médecine interne, Centre de référence des maladies auto-immunes systémiques rares, hôpital Huriez, CHU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France.

Purpose: Therapeutic education (TE) intends to help patients with systemic lupus erythematosus to better understand their disease and to improve their quality of life. The objective of this study was to assess illness perceptions of the person to provide a motivational environment for TE.

Methods: Systemic lupus erythematosus patients followed in the department of internal medicine in Lille university hospital responded to a questionnaire assessing five dimensions of the person as proposed by Giordan: the cognitive (knowledge), perceptual (fatigue and pain), affective (anxious and depressive symptoms), infra-cognitive (intimate reasoning) and metacognitive (worldview) dimensions. Read More

View Article
December 2018

Hepatitis A virus vaccination in childhood-onset systemic lupus erythematosus.

Lupus 2018 Dec 14:961203318819827. Epub 2018 Dec 14.

1 Department of Pediatric Rheumatology, Istanbul University, Istanbul, Turkey.

Objectives: Vaccination of systemic lupus erythematosus patients with non-live vaccines may decrease vaccine-preventable infections and mortalities. In the present study, we aimed to compare the immunogenicity and safety of inactivated hepatitis A vaccination in childhood-onset systemic lupus erythematosus and healthy subjects.

Methods: A total of 30 childhood-onset systemic lupus erythematosus and 39 healthy participants who were seronegative for hepatitis A received two doses of the hepatitis A vaccine in a 0- and 6-month schedule. Read More

View Article
December 2018
1 Read

A Flow Cytometry-Based Assay for High-Throughput Detection and Quantification of Neutrophil Extracellular Traps in Mixed Cell Populations.

Cytometry A 2018 Dec 14. Epub 2018 Dec 14.

Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Neutrophil extracellular traps (NETs) are web-like structures composed of decondensed chromatin and antimicrobial proteins that are released into the extracellular space during microbial infections. This active cell death program is known as NETosis. To date, florescence microscopy is the widely accepted method for visualization and quantification of NETs. Read More

View Article
December 2018

Two cases of lupus arteritis: a rare type of cutaneous lupus vasculitis.

Int J Dermatol 2018 Dec 11. Epub 2018 Dec 11.

Department of Dermatology, Fukushima Medical University, Fukushima, Japan.

View Article
December 2018

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review.

Pediatr Rheumatol Online J 2018 Dec 14;16(1):79. Epub 2018 Dec 14.

Department of Rheumatology, Ajou University of medical school, 164 Worldcup-ro, Yeongtong-gu, Suwon, 16499, Republic of Korea.

Tocilizumab, an anti-interleukin-6 (IL-6) agent, is indicated as a treatment for several autoimmune or inflammatory diseases, including rheumatoid arthritis and juvenile idiopathic arthritis (JIA). IL-6 plays roles in both immune system dysregulation and inflammation, and thus efforts to extend the utility of tocilizumab in patients with autoinflammatory conditions are ongoing. Here, we survey the literature on the off-label use of tocilizumab in patients with juvenile-onset rheumatic diseases including juvenile systemic lupus erythematosus (SLE), juvenile dermatomyositis (DM), vasculitis, juvenile scleroderma, and other autoinflammatory diseases. Read More

View Article
December 2018
1 Read

Leptotrichia trevisanii bacteremia in a woman with systemic lupus erythematosus receiving high-dose chemotherapy.

BMC Infect Dis 2018 Dec 14;18(1):661. Epub 2018 Dec 14.

Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Road 1095#, Wuhan, 430030, China.

Background: Leptotrichia species are aerotolerant, Gram-negative fusiform bacteria. Cases of bacteremia caused by Leptotrichia trevisanii in immunocompromised patients have been rarely reported.

Case Presentation: A 33-year-old female with systemic lupus erythematosus (SLE) was admitted to the department of rheumatology with bleeding from a mucosal ulcer. Read More

View Article
December 2018
2 Reads

Alpha 1 Antitrypsin Gene Therapy Extends the Lifespan of Lupus-Prone Mice.

Mol Ther Methods Clin Dev 2018 Dec 18;11:131-142. Epub 2018 Oct 18.

Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by high levels of pathogenic autoantibodies and tissue damage. Multiple studies showed that dendritic cell (DC) activation plays a critical role in SLE pathogenesis. Human alpha 1 antitrypsin (hAAT) is a serine proteinase inhibitor with potent anti-inflammatory and cytoprotective properties. Read More

View Article
December 2018

Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis.

Clin Transl Immunology 2018 6;7(12):e1042. Epub 2018 Dec 6.

Centre for Inflammatory Diseases School of Clinical Sciences at Monash Health Monash University Clayton VIC Australia.

Objectives: Macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (DDT), members of the same cytokine superfamily, are linked to the pathogenesis of a number of inflammatory diseases. The aim of this study was to investigate their clinical relevance in systemic sclerosis (SSc).

Methods: Serum MIF and DDT were quantified in 105 SSc patients by ELISA and levels compared to healthy controls (HC) (47) and patients with systemic lupus erythematosus (SLE) (184). Read More

View Article
December 2018

Postpartum flare up of systemic lupus erythematosus: Pulmonary diffused alveolar hemorrhage.

Taiwan J Obstet Gynecol 2018 Dec;57(6):906-907

Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. Electronic address:

View Article
December 2018

The Impact of Protein Acetylation/Deacetylation on Systemic Lupus Erythematosus.

Int J Mol Sci 2018 Dec 12;19(12). Epub 2018 Dec 12.

Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA 24060, USA.

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease in which the body's immune system mistakenly attacks healthy cells. Although the exact cause of SLE has not been identified, it is clear that both genetics and environmental factors trigger the disease. Identical twins have a 24% chance of getting lupus disease if the other one is affected. Read More

View Article
December 2018
1 Read

Neurological and Inflammatory Manifestations in Sjögren's Syndrome: The Role of the Kynurenine Metabolic Pathway.

Int J Mol Sci 2018 Dec 8;19(12). Epub 2018 Dec 8.

Ribeirao Preto Medical School, Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP 14049-900 Brazil.

For decades, neurological, psychological, and cognitive alterations, as well as other glandular manifestations (EGM), have been described and are being considered to be part of Sjögren's syndrome (SS). Dry eye and dry mouth are major findings in SS. The lacrimal glands (LG), ocular surface (OS), and salivary glands (SG) are linked to the central nervous system (CNS) at the brainstem and hippocampus. Read More

View Article
December 2018

Relapsing Evans syndrome and systemic lupus erythematosus with antiphospholipid syndrome treated with Bortezomib in combination with plasma exchange.

Clin Immunol 2018 Dec 10. Epub 2018 Dec 10.

Laboratory of the Mosaics of Autoimmunity, Saint-Petersburg University, 7/9 Universitetskaya Emb., Saint- Petersburg 199034, Russia.

Relapsing Evans syndrome (ES) and systemic lupus erythematosus (SLE) with secondary antiphospholipid syndrome (APS) is very rare association. Coexistence of these syndromes is potentially fatal and require high-dose combined immunosuppressive therapy. We describe a case of successful use of Bortezomib and plasma exchange in a patient with ES and APS refractory to standard therapy. Read More

View Article
December 2018

T cell receptor revision and immune repertoire changes in autoimmune diseases.

Clin Immunol 2018 Dec 10. Epub 2018 Dec 10.

Department of Endocrinology, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China. Electronic address:

Autoimmune disease (AID) is a condition in which the immune system breaks down and starts to attack the body. Some common AIDs include rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes mellitus and so forth. The changes in T-cell receptor (TCR) repertoire have been found in several autoimmune diseases, and may be responsible for the breakdown of peripheral immune tolerance. Read More

View Article
December 2018

Correlation between active disease and hypercoagulability state in patients with systemic lupus erythematosus.

Clin Chim Acta 2018 Dec 10. Epub 2018 Dec 10.

Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil. Electronic address:

Objective: This study has investigated whether high levels of Reticulocytes-C4d (R-C4d) and Platelets-C4d (P-C4d) reflecting recent activity in SLE patients are correlated with changes in natural anticoagulation components, coagulation activation and endothelial injury markers.

Methods: This study included three groups: 1) healthy women (control, n = 30); 2) women with low activity of the disease (SLEDAI 2 K ≤ 4, n = 30); 3) women with active disease (moderate or high activity) (SLEDAI 2 K > 4, n = 30). Median fluorescence intensity (MFI) of R-C4d and P-C4d were determined by flow cytometry using double labeling with specific monoclonal antibodies. Read More

View Article
December 2018
1 Read

The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome.

Front Pediatr 2018 27;6:362. Epub 2018 Nov 27.

Department of Rheumatology, University College London, London, United Kingdom.

Antiphospholipid syndrome (APS) is a rare autoimmune disease of unknown etiology that represents a leading cause of acquired thromboembolism and recurrent miscarriage. It is characterized by the persistent elevated presence of pathogenic antiphospholipid auto-antibodies directed against cardiolipin, ß2-glycoprotein-I, and/or a positive lupus anticoagulant test. As with many autoimmune disorders, the pathogenesis of APS is believed to be the result of a complex interaction between environmental triggers and genetic predisposition. Read More

View Article
November 2018

Deficiency of β-Arrestin 2 in Dendritic Cells Contributes to Autoimmune Diseases.

J Immunol 2018 Dec 12. Epub 2018 Dec 12.

Putuo District People's Hospital, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China;

Altered migration and immune responses of dendritic cells (DCs) lead to inflammatory and autoimmune diseases. Our studies demonstrated that β-arrestin 2 deficiency promoted migration and cytokine production of mouse bone marrow-derived DCs. We further found that β-arrestin 2 directly interacted with Zbtb46, a DC-specific transcription factor. Read More

View Article
December 2018

SLE dacryoadenitis.

Orbit 2018 Dec 12:1-4. Epub 2018 Dec 12.

a Department of Ophthalmology , Christchurch Hospital , Christchurch , New Zealand.

In systemic lupus erythematosus, ophthalmic manifestations are noted in up to one-third of patients. We describe a patient with an unusual initial presentation of this disorder. Read More

View Article
December 2018

Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab.

Front Immunol 2018 20;9:2698. Epub 2018 Nov 20.

Department of Biochemistry, University of Lausanne, Lausanne, Switzerland.

B cell activating factor of the TNF family (BAFF, also known as BLyS), a cytokine that regulates homeostasis of peripheral B cells, is elevated in the circulation of patients with autoimmune diseases such as systemic lupus erythematosus (SLE). BAFF is synthetized as a membrane-bound protein that can be processed to a soluble form after cleavage at a furin consensus sequence, a site that in principle can be recognized by any of the several proteases of the pro-protein convertase family. Belimumab is a human antibody approved for the treatment of SLE, often cited as specific for the soluble form of BAFF. Read More

View Article
November 2018

Novel Treatments in Lupus.

Front Immunol 2018 16;9:2658. Epub 2018 Nov 16.

Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

Purpose Of Review: The standard treatment options for systemic lupus erythematosus (SLE) are focused on non-specific immunosuppression. Over the past few years, scientific studies and ongoing clinical trials have shifted the paradigm with rapid advances in developing biologics and small molecules. A number of monoclonal antibodies and small molecule inhibitors have been developed to target specific pathways involved in SLE. Read More

View Article
November 2018
1 Read

Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome.

Front Immunol 2018 20;9:2644. Epub 2018 Nov 20.

Immunology Department, Hospital 12 de Octubre, Madrid, Spain.

Antiphospholipid syndrome (APS) is an acquired autoimmune disorder defined by the presence of both clinical (thromboembolic events or pregnancy morbidity) and laboratory (antiphospholipid antibodies, aPL) manifestations. Despite their importance, several clinical manifestations strongly associated with APS such as livedo reticularis (LR), thrombocytopenia, sicca-ophthalmic(sicca), heart, or neurological manifestations are not included in the APS clinical classification criteria. Circulating immune complexes (CIC) formed by Beta-2-glycoprotein I (B2GPI) and aPL (B2-CIC) have been described and their presence has been related with thrombotic events. Read More

View Article
November 2018

Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre.

Clin Rheumatol 2018 Dec 6. Epub 2018 Dec 6.

Department of Rheumatology, Institute of Post Graduate Medical Education and Research, 240 AJC Bose Road, Kolkata, West Bengal, India.

Objective: Whether maintaining steroid-free remission is feasible in Indian patients with systemic lupus erythematosus (SLE).

Methods: In 148 patients with SLE including 78 lupus nephritis (LN) previously put into remission, steroid therapy was gradually tapered off.

Results: Patients received glucocorticoids for median 1855 days (interquartile range (IQR) 901-2834) before discontinuing. Read More

View Article
December 2018
1.774 Impact Factor

Metabolic fingerprinting for diagnosis of fibromyalgia and other rheumatologic disorders.

J Biol Chem 2018 Dec 6. Epub 2018 Dec 6.

The Ohio State University, Food Science and Technology, United States.

Diagnosis and treatment of Fibromyalgia (FM) remains a challenge owing to the lack of reliable biomarkers. Our objective was to develop a rapid biomarker-based method for diagnosing FM by using vibrational spectroscopy to differentiate patients with FM from those with Rheumatoid Arthritis (RA), Osteoarthritis (OA) or Systemic Lupus Erythematosus (SLE), and to identify metabolites associated with these differences. Blood samples were collected from patients with a diagnosis of FM (n=50), RA (n=29), OA (n=19), or SLE (n=23). Read More

View Article
December 2018

Coexistence of Systemic Lupus Erythematosus and Myasthenia Gravis: An Unusual Case of Polyautoimmunity.

Reumatol Clin 2018 Dec 3. Epub 2018 Dec 3.

Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia.

The relevance of polyautoimmunity, defined as the presence of 2or more autoimmune diseases in the same individual, is one of the issues not yet elucidated in medical practice. The coexistence of myasthenia gravis (MG) and systemic lupus erythematosus (SLE) is a clinical challenge due to the possible differential diagnoses of muscle involvement in patients with SLE. We present the case of a patient who came to the emergency room of Hospital Universitario San Ignacio in Bogotá, Colombia, with a previous diagnosis of SLE, who developed acute weakness in the context of a systemic infection, with a clinical and electrophysiological diagnosis of MG. Read More

View Article
December 2018

Effectiveness and Safety of Rituximab in Systemic Lupus Erythematosus: A Case Series Describing the Experience of 2 Centers.

Reumatol Clin 2018 Dec 3. Epub 2018 Dec 3.

Servicio de Reumatología, Hospital del Mar/Parc de Salut-Mar/IMIM, Barcelona, España.

Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs and systems. B cells have a critical role in the pathogenesis of SLE. Rituximab (RTX) is a drug composed of chimeric monoclonal antibodies against the CD20 protein, producing a depletion of B lymphocytes. Read More

View Article
December 2018

[Thrombophilia in systemic lupus erythematosus: A case-control study].

J Med Vasc 2018 Dec 31;43(6):347-353. Epub 2018 Oct 31.

Service de médecine interne, CHU la Rabta de Tunis, rue Jbel Lakhdar,La Rabta Jebbari, 1007 Tunis, Tunisie.

Introduction: To investigate the thrombotic tendency in patients with systemic lupus erythematosus (SLE) by evaluating congenital and acquired abnormalities with an increased risk of thrombosis.

Patients And Methods: A total of 53 patients with SLE were included in the study. Fifty-three healthy controls paired by age and sex were assessed. Read More

View Article
December 2018

CD84 cell surface signaling molecule: An emerging biomarker and target for cancer and autoimmune disorders.

Clin Immunol 2018 Oct 26. Epub 2018 Oct 26.

Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

CD84 (SLAMF5) is a member of the SLAM family of cell-surface immunoreceptors. Broadly expressed on most immune cell subsets, CD84 functions as a homophilic adhesion molecule, whose signaling can activate or inhibit leukocyte function depending on the cell type and its stage of activation or differentiation. CD84-mediated signaling regulates diverse immunological processes, including T cell cytokine secretion, natural killer cell cytotoxicity, monocyte activation, autophagy, cognate T:B interactions, and B cell tolerance at the germinal center checkpoint. Read More

View Article
October 2018

The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis.

Arthritis Res Ther 2018 Dec 6;20(1):270. Epub 2018 Dec 6.

Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, China.

Background: Although accumulating data have suggested the development of cancer in systemic lupus erythematosus (SLE) patients, these results remain inconsistent. To examine such a putative association, this analysis reports the association between SLE and the risks of 24 cancer types.

Methods: Online databases PubMed, EMBASE, and Web of Science were searched comprehensively for eligible studies, published up to 15 May 2018. Read More

View Article
December 2018

Intravitreal dexamethasone implant therapy for the treatment of cystoid macular Oedema due to hydroxychloroquine retinopathy: a case report and literature review.

BMC Ophthalmol 2018 Dec 6;18(1):310. Epub 2018 Dec 6.

Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, #17 Haengdang-dong, Seongdong-gu, Seoul, 133-792, South Korea.

Background: Cystoid macular oedema (CMO) is an uncommon complication associated with hydroxychloroquine (HCQ) retinopathy threatening central vision. We report a patient with HCQ retinopathy and CMO, for which an intravitreal dexamethasone implant was used, which led to complete resolution of oedema.

Case Presentation: A 57-year-old woman with systemic lupus erythematosus (SLE) complaining of blurred vision in both eyes was diagnosed with bilateral HCQ retinopathy and CMO based on characteristic photoreceptor defects and cystoid spaces on optical coherence tomography, hypo-autofluorescence on fundus autofluorescence, and corresponding visual field defects. Read More

View Article
December 2018

Is systemic lupus erythematosus different in urban versus rural living environment? Data from the Cretan Lupus Epidemiology and Surveillance Registry.

Lupus 2018 Dec 6:961203318816820. Epub 2018 Dec 6.

1 Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Iraklio, Greece.

Background: Examining urban-rural differences can provide insights into susceptibility or modifying factors of complex diseases, yet limited data exist on systemic lupus erythematosus (SLE).

Objective: To study SLE risk, manifestations and severity in relation to urban versus rural residence.

Methodology: Cross-sectional analysis of the Crete Lupus Registry. Read More

View Article
December 2018

Provider perceptions on the management of lupus during pregnancy: barriers to improved care.

Lupus 2018 Dec 6:961203318815594. Epub 2018 Dec 6.

3 Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA; Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina, USA.

Background: More than half of pregnancies in women with systemic lupus erythematosus (lupus) result in adverse outcomes for the mother or the fetus. We sought to identify aspects of current rheumatologic care that could be improved to decrease the frequency of poor outcomes.

Methods: Focus groups with clinical rheumatologists, based on the PRECEDE/PROCEED framework, identified factors that influenced care. Read More

View Article
December 2018

Comment on: Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus.

Rheumatology (Oxford) 2018 Dec 11. Epub 2018 Dec 11.

Department of Internal Medicine, Tenon Hospital (AP-HP), Paris, France.

View Article
December 2018

Neutrophils in lupus nephritis.

Curr Opin Rheumatol 2018 Dec 11. Epub 2018 Dec 11.

Center for Excellence in Vascular Biology, Department of Pathology, Brigham and Women's Hospital & Harvard Medical School, Boston, USA.

Purpose Of Review: Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease characterized by IgG-autoantibodies to nuclear antigens that can deposit in the kidney and trigger lupus nephritis. Neutrophils accumulate in the kidneys of patients with proliferative LUPUS NEPHRITIS and neutrophil products and a subset of granulocytes, called low-density granulocytes (LDG) may contribute to lupus nephritis pathogenesis. Here, we will discuss recent studies implicating neutrophils in the pathogenesis of human SLE nephritis and then examine studies that provide mechanistic insights into how these cells are recruited to the glomerulus following immune complex deposition and how their products may promote lupus nephritis. Read More

View Article
December 2018
1 Read

Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations.

Curr Opin Rheumatol 2018 Dec 11. Epub 2018 Dec 11.

Department of Medicine/Rheumatology and Clinical Immunology.

Purpose Of Review: This review summarizes recent insights and current understanding of the role of postactivated B cells in SLE and related pathogenic and potential therapeutic implications.

Recent Finding: B cells are considered key players in SLE and experience from various B-cell-targeted therapies underlines their clinical relevance. In the last years, new insights have been obtained on B-cell abnormality within the complex pathophysiology of SLE. Read More

View Article
December 2018
1 Read

Gene-function studies in SLE.

Curr Opin Rheumatol 2018 Dec 11. Epub 2018 Dec 11.

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.

Purpose Of Review: The aim of this review is to discuss recent developments in our understanding of how systemic lupus erythematosus (SLE)-associated genes contribute to autoimmunity.

Recent Findings: Gene-function studies have revealed mechanisms through which SLE-associated alleles of IFIH1, TNFAIP3, IRF5, and PRDM1 likely contribute to the development of autoimmunity. Novel research has identified Mac-1 (encoded by ITGAM), CaMK4, and iRhom2 as plausible therapeutic targets in lupus nephritis. Read More

View Article
December 2018
2 Reads

rs2217560 was Associated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus.

Chin Med J (Engl) 2018 Dec;131(24):3020-3021

Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.

View Article
December 2018
1.016 Impact Factor